Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Disodium Gadoxetate
2. Eovist
3. Gadolinium (4s)-4-(4-ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanoic Acid Disodium Salt
4. Gadolinium Ethoxybenzyl Diethylenetriaminepentaacetic Acid
5. Gadolinium Ethoxybenzyl Dtpa
6. Gadoxetate Disodium
7. Gadoxetic Acid
8. Gadoxetic Acid Disodium
9. Gd-eob-dtpa
1. Eovist
2. Gadoxate
3. Gadoxate Disodium
4. Gadolinium Ethoxybenzyl-dtpa
5. Moli000482
6. Q1928394
7. 2-[[2-[bis(carboxymethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxymethyl)amino]ethyl]amino]acetic Acid;gadolinium(3+)
8. Gadolinium-ethoxybenzyl-diethylenetriaminepentaacetic Acid, Disodium S-[4-(4-ethoxybenzyl)-3,6,9-tris[(carboxy-ko)methyl]-3,6,9-triazaundecandioato)(5-)-k3n3,n6,n9,k2o1,o11]gadolinite(2-)
| Molecular Weight | 684.8 g/mol |
|---|---|
| Molecular Formula | C23H33GdN3O11+3 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 20 |
| Exact Mass | 685.13562 g/mol |
| Monoisotopic Mass | 685.13562 g/mol |
| Topological Polar Surface Area | 205 Ų |
| Heavy Atom Count | 38 |
| Formal Charge | 3 |
| Complexity | 739 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Eovist |
| PubMed Health | Gadoxetate (Injection) |
| Drug Classes | Diagnostic Agent |
| Drug Label | EOVIST (gadoxetate disodium) is a paramagnetic contrast agent for MRI. EOVIST is provided as a sterile, clear, colorless to pale yellow aqueous solution for intravenous injection.EOVIST contains the active pharmaceutical ingredient gadoxetate disodiu... |
| Active Ingredient | Gadoxetate disodium |
| Dosage Form | Solution |
| Route | Intravenous |
| Strength | 1.8143gm/10ml (181.43mg/ml); 2.72145gm/15ml (181.43mg/ml) |
| Market Status | Prescription |
| Company | Bayer Hlthcare |
| 2 of 2 | |
|---|---|
| Drug Name | Eovist |
| PubMed Health | Gadoxetate (Injection) |
| Drug Classes | Diagnostic Agent |
| Drug Label | EOVIST (gadoxetate disodium) is a paramagnetic contrast agent for MRI. EOVIST is provided as a sterile, clear, colorless to pale yellow aqueous solution for intravenous injection.EOVIST contains the active pharmaceutical ingredient gadoxetate disodiu... |
| Active Ingredient | Gadoxetate disodium |
| Dosage Form | Solution |
| Route | Intravenous |
| Strength | 1.8143gm/10ml (181.43mg/ml); 2.72145gm/15ml (181.43mg/ml) |
| Market Status | Prescription |
| Company | Bayer Hlthcare |
Contrast Media
Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : Complete
Rev. Date : 2025-11-12
Pay. Date : 2025-09-17
DMF Number : 41810
Submission : 2025-07-31
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20414
Submission : 2007-05-14
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39660
Submission : 2024-04-01
Status : Inactive
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Details:
Gadoxetate Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Oligometastatic Disease.
Lead Product(s): Gadolinium Ethoxybenzyl Dtpa,Gadobenic Acid
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Bracco | National Cancer Institute
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 22, 2021

Lead Product(s) : Gadolinium Ethoxybenzyl Dtpa,Gadobenic Acid
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Bracco | National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases
Details : Gadoxetate Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Oligometastatic Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 22, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Gadoxetate Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Motor Disorders.
Lead Product(s): Gadolinium Ethoxybenzyl Dtpa,Gadobenic Acid,Gadodiamide
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Bayer AG | Bracco | GE Healthcare
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 04, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Gadolinium Ethoxybenzyl Dtpa,Gadobenic Acid,Gadodiamide
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Bayer AG | Bracco | GE Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gadoxetate Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Motor Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 04, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Gadoxetate Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Carcinoma, Hepatocellular.
Lead Product(s): Gadolinium Ethoxybenzyl Dtpa,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Nova Scotia Health Authority
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 12, 2017

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Gadolinium Ethoxybenzyl Dtpa,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Nova Scotia Health Authority
Deal Size : Inapplicable
Deal Type : Inapplicable
Improving CBCT for Liver IG-SBRT Using Gadoxetate Disodium
Details : Gadoxetate Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 12, 2017

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Gadoxetate Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Lead Product(s): Gadolinium Ethoxybenzyl Dtpa,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 12, 2014

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Gadolinium Ethoxybenzyl Dtpa,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gadoxetate Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 12, 2014

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CAS Number : 75-03-6
End Use API : Gadolinium Ethoxybenzyl Dtpa
About The Company : At Infinium Pharmachem Pvt. Ltd., we are well focused to Iodine chemistry & this is the only core area of ours. We are working as CRAMS, but our domain is very ...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Primovist
Dosage Form : SOL
Dosage Strength : 600mg
Packaging : 10X1mg/ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Application : Parenteral
Excipient Details : Tris (hydroxymethyl) aminomethane is used in electrophoresis, protein purification, enzyme assay, and as a buffering agent in biologics production.
Pharmacopoeia Ref : USP, EP, BP, ChP
Technical Specs : Low Endotoxin, Low Metals
Ingredient(s) : Tromethamine
Application : Parenteral
Excipient Details : Tris (hydroxymethyl) aminomethane is a buffering agent used in cell culture, downstream and biological formulations.
Pharmacopoeia Ref : On Request
Technical Specs : Low bacteria endotoxins, low bioburden (TAMC/TYMC). Customised pa...
Ingredient(s) : Tromethamine
Dosage Form : Cream / Lotion / Ointment, Injectable / Parenteral
Grade : Topical, Parenteral
Category : Parenteral, Topical
Brand Name : Tromethamine (Tris)
Application : Parenteral, Topical
Excipient Details : It stabilizes the pH of solutions. It is also an enzyme inhibitor used in the biopharmaceutical industry.
Pharmacopoeia Ref : Not Available
Technical Specs : Bio Excipient Grade
Ingredient(s) : Tromethamine
Brand Name : Hydrochloric Acid NF
Application : Parenteral
Excipient Details : A&C's Hydrochloric Acid NF is used as a low pH neutralizing agent for pharmaceutical applications.
Excipients Web Link
Market Place
Reply
14 Dec 2024
Reply
13 Jun 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
ABOUT THIS PAGE
24
PharmaCompass offers a list of Gadolinium Ethoxybenzyl Dtpa API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Gadolinium Ethoxybenzyl Dtpa manufacturer or Gadolinium Ethoxybenzyl Dtpa supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Gadolinium Ethoxybenzyl Dtpa manufacturer or Gadolinium Ethoxybenzyl Dtpa supplier.
A Gadolinium Ethoxybenzyl Dtpa manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Gadolinium Ethoxybenzyl Dtpa, including repackagers and relabelers. The FDA regulates Gadolinium Ethoxybenzyl Dtpa manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Gadolinium Ethoxybenzyl Dtpa API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Gadolinium Ethoxybenzyl Dtpa manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Gadolinium Ethoxybenzyl Dtpa supplier is an individual or a company that provides Gadolinium Ethoxybenzyl Dtpa active pharmaceutical ingredient (API) or Gadolinium Ethoxybenzyl Dtpa finished formulations upon request. The Gadolinium Ethoxybenzyl Dtpa suppliers may include Gadolinium Ethoxybenzyl Dtpa API manufacturers, exporters, distributors and traders.
click here to find a list of Gadolinium Ethoxybenzyl Dtpa suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Gadolinium Ethoxybenzyl Dtpa DMF (Drug Master File) is a document detailing the whole manufacturing process of Gadolinium Ethoxybenzyl Dtpa active pharmaceutical ingredient (API) in detail. Different forms of Gadolinium Ethoxybenzyl Dtpa DMFs exist exist since differing nations have different regulations, such as Gadolinium Ethoxybenzyl Dtpa USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Gadolinium Ethoxybenzyl Dtpa DMF submitted to regulatory agencies in the US is known as a USDMF. Gadolinium Ethoxybenzyl Dtpa USDMF includes data on Gadolinium Ethoxybenzyl Dtpa's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Gadolinium Ethoxybenzyl Dtpa USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Gadolinium Ethoxybenzyl Dtpa suppliers with USDMF on PharmaCompass.
A Gadolinium Ethoxybenzyl Dtpa written confirmation (Gadolinium Ethoxybenzyl Dtpa WC) is an official document issued by a regulatory agency to a Gadolinium Ethoxybenzyl Dtpa manufacturer, verifying that the manufacturing facility of a Gadolinium Ethoxybenzyl Dtpa active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Gadolinium Ethoxybenzyl Dtpa APIs or Gadolinium Ethoxybenzyl Dtpa finished pharmaceutical products to another nation, regulatory agencies frequently require a Gadolinium Ethoxybenzyl Dtpa WC (written confirmation) as part of the regulatory process.
click here to find a list of Gadolinium Ethoxybenzyl Dtpa suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Gadolinium Ethoxybenzyl Dtpa as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Gadolinium Ethoxybenzyl Dtpa API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Gadolinium Ethoxybenzyl Dtpa as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Gadolinium Ethoxybenzyl Dtpa and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Gadolinium Ethoxybenzyl Dtpa NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Gadolinium Ethoxybenzyl Dtpa suppliers with NDC on PharmaCompass.
Gadolinium Ethoxybenzyl Dtpa Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Gadolinium Ethoxybenzyl Dtpa GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Gadolinium Ethoxybenzyl Dtpa GMP manufacturer or Gadolinium Ethoxybenzyl Dtpa GMP API supplier for your needs.
A Gadolinium Ethoxybenzyl Dtpa CoA (Certificate of Analysis) is a formal document that attests to Gadolinium Ethoxybenzyl Dtpa's compliance with Gadolinium Ethoxybenzyl Dtpa specifications and serves as a tool for batch-level quality control.
Gadolinium Ethoxybenzyl Dtpa CoA mostly includes findings from lab analyses of a specific batch. For each Gadolinium Ethoxybenzyl Dtpa CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Gadolinium Ethoxybenzyl Dtpa may be tested according to a variety of international standards, such as European Pharmacopoeia (Gadolinium Ethoxybenzyl Dtpa EP), Gadolinium Ethoxybenzyl Dtpa JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Gadolinium Ethoxybenzyl Dtpa USP).